A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti tumour activity.

Research output: Contribution to journalArticle

Bibtex

@article{7101089a216540e6bc7ae5d5e3a9d4b2,
title = "A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti tumour activity.",
abstract = "The Tn antigen (GalNAc alpha-O-Ser/Thr) is heterogeneously synthesised by a variety of tumours and contains an epitope defined by lectins and antibodies as a cluster of alpha GalNAc carbohydrates synthesised within a peptide sequence, which is rich in serine and/or threonine. The Tn antigen has been utilized as a target in vaccine experiments and also used as a biomarker for prognosis of different cancer forms. In this paper we present a new monoclonal antibody, GOD3-2C4, with the clear hallmarks of an anti-Tn antibody. It was generated through somatic cell hybridisation after immunisation of a mouse with a tumour cell line and a Tn carrying mucin. The antibody recognises synthetic Tn antigen and binds breast, colon, lung, ovarian and pancreas cancer. The GOD3-2C4 antibody has ADCC activity against Jurkat cells in vitro and for the first time it can be shown that an anti-Tn antibody has a significant in vivo effect on a human cancer cell line grown as a xenograft in SCID mice.",
keywords = "monoclonal antibody, in vivo therapy, antigen, Tn, anti-carbohydrate, biomarker",
author = "Charlotte Welinder and Bo Baldetorp and Carl Borrebaeck and Britt-Marie Fredlund and Bo Jansson",
year = "2011",
doi = "10.1093/glycob/cwr048",
language = "English",
volume = "21",
pages = "1097--1107",
journal = "Glycobiology",
issn = "1460-2423",
publisher = "Oxford University Press",
number = "8",

}